A new index for non-invasive assessment of liver fibrosis

Table 1 Characteristics of the 165 patients in the estimation group and the 120 patients in the validation group (mean ± SD)

	All patients (n = 285)	Estimation group (n = 165)	Validation group (n = 120)	P-value
Male gender, n (%)	149 (52.3)	92 (55.8)	57 (47.5)	NS
Age (yr)	52.4 ± 13.3	53.2 ± 12.6	51.5 ± 14.2	NS
Liver stiffness (kPa)	9.99 ± 6.99	10.29 ± 7.33	9.58 ± 6.51	NS
Platelet count (× 104/mL)	16.54 ± 5.28	16.53 ± 5.41	16.57 ± 5.13	NS
Prothrombin time (%)	9.35 ± 11.3	92.4 ± 10.2	95.1 ± 12.6	NS
AST (IU/L)	52.5 ± 34.0	53.0 ± 34.6	51.8 ± 33.4	NS
ALT (IU/L)	70.8 ± 52.6	72.4 ± 54.9	68.7 ± 49.4	NS
Total protein (g/dL)	7.81 ± 0.52	7.79 ± 0.49	7.85 ± 0.57	NS
Albumin (g/dL)	4.31 ± 0.34 (n = 283)	4.31 ± 0.31 (n = 163)	4.31 ± 0.38	NS
γ-GTP (IU/L)	59.8 ± 62.0	58.1 ± 57.9	62.1 ± 67.5	NS
γ-globulin (g/dL)	1.57 ± 0.41 (n = 276)	1.54 ± 0.38 (n = 146)	16.1 ± 0.44	NS
Total cholesterol (mg/dL)	178.1 ± 31.9	177.2 ± 31.1	179.5 ± 33.0	NS
Hyaluronic acid (ng/mL)	104.1 ± 128.3 (n = 281)	114.5 ± 140.0 (n = 161)	90.0 ± 109.3	NS
Fibrosis stage, n (%)
F0	28 (9.8)	14 (8.5)	14 (11.7)
F1	85 (29.8)	52 (31.5)	33 (27.5)
F2	82 (28.8)	42 (25.5)	40 (33.3)
F3	53 (18.6)	33 (20.0)	20 (16.7)
F4	37 (13.0)	24 (14.5)	13 (10.8)

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; NS: Not significant.